Home  »  Hot Stocks   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) went up by 2.64% from its latest closing price compared to the recent 1-year high of $11.59. The company’s stock price has collected -1.69% of loss in the last five trading sessions. The Wall Street Journal reported on 05/11/22 that This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed

Is It Worth Investing in Nektar Therapeutics (NASDAQ :NKTR) Right Now?

Plus, the 36-month beta value for NKTR is at 0.93. Opinions of the stock are interesting as 0 analysts out of 9 who provided ratings for Nektar Therapeutics declared the stock was a “buy,” while 0 rated the stock as “overweight,” 7 rated it as “hold,” and 1 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $4.41, which is $2.08 above the current price. NKTR currently public float of 185.37M and currently shorts hold a 4.85% ratio of that float. Today, the average trading volume of NKTR was 1.57M shares.

NKTR’s Market Performance

NKTR stocks went down by -1.69% for the week, with a monthly jump of 1.30% and a quarterly performance of -34.73%, while its annual performance rate touched -79.16%. The volatility ratio for the week stands at 5.81% while the volatility levels for the past 30 days are set at 6.81% for Nektar Therapeutics. The simple moving average for the period of the last 20 days is 1.06% for NKTR stocks with a simple moving average of -36.22% for the last 200 days.

Analysts’ Opinion of NKTR

Jefferies, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $4, previously predicting the price at $12. The rating they have provided for NKTR stocks is “Hold” according to the report published on May 31st, 2022.

Goldman gave a rating of “Sell” to NKTR, setting the target price at $3 in the report published on April 18th of the previous year.

NKTR Trading at -15.88% from the 50-Day Moving Average

After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.90% of loss for the given period.

Volatility was left at 6.81%, however, over the last 30 days, the volatility rate increased by 5.81%, as shares surge +8.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.10% lower at present.

During the last 5 trading sessions, NKTR fell by -1.69%, which changed the moving average for the period of 200-days by -59.62% in comparison to the 20-day moving average, which settled at $2.31. In addition, Nektar Therapeutics saw 3.10% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 13,460 shares at the price of $3.57 back on Nov 16. After this action, Zalevsky Jonathan now owns 313,663 shares of Nektar Therapeutics, valued at $48,052 using the latest closing price.

Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 8,690 shares at $3.57 during a trade that took place back on Nov 16, which means that Wilson Mark Andrew is holding 272,498 shares at $31,023 based on the most recent closing price.

Stock Fundamentals for NKTR

Current profitability levels for the company are sitting at:

  • -437.76 for the present operating margin
  • +65.93 for the gross margin

The net margin for Nektar Therapeutics stands at -514.03. Equity return is now at value -84.20, with -48.00 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.34.

Is SSR Mining Inc. (SSRM) a Keeper?

SSR Mining Inc. (NASDAQ:SSRM) went down by -3.03% from its latest closing price compared to the recent 1-year high of $24.58. The company’s stock price